Skip to main content
Erschienen in: Clinical and Translational Oncology 7/2017

16.01.2017 | Research Article

Cancer incidence in Spain, 2015

verfasst von: J. Galceran, A. Ameijide, M. Carulla, A. Mateos, J. R. Quirós, D. Rojas, A. Alemán, A. Torrella, M. Chico, M. Vicente, J. M. Díaz, N. Larrañaga, R. Marcos-Gragera, M. J. Sánchez, J. Perucha, P. Franch, C. Navarro, E. Ardanaz, J. Bigorra, P. Rodrigo, R. Peris Bonet, REDECAN Working Group

Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Periodic cancer incidence estimates of Spain from all existing population-based cancer registries at any given time are required. The objective of this study was to present the current situation of cancer incidence in Spain.

Methods

The Spanish Network of Cancer Registries (REDECAN) estimated the numbers of new cancer cases occurred in Spain in 2015 by applying the incidence-mortality ratios method. In the calculus, incidence data from population-based cancer registries and mortality data of all Spain were used.

Results

In 2015, nearly a quarter of a million new invasive cancer cases were diagnosed in Spain, almost 149,000 in men (60.0%) and 99,000 in women. Globally, the five most common cancers were those of colon–rectum, prostate, lung, breast and urinary bladder. By gender, the four most common cancers in men were those of prostate (22.4%), colon–rectum (16.6%), lung (15.1%) and urinary bladder (11.7%). In women, the most common ones were those of breast (28.0%), colon–rectum (16.9%), corpus uteri (6.2%) and lung (6.0%). In recent years, cancer incidence in men seems to have stabilized due to the fact that the decrease in tobacco-related cancers compensates for the increase in other types of cancer like those of colon and prostate. In women, despite the stabilization of breast cancer incidence, increased incidence is due, above all, to the rise of colorectal and tobacco-related cancers.

Conclusion

To reduce these incident cancer cases, improvement of smoking control policies and extension of colorectal cancer screening should be the two priorities in cancer prevention for the next years.
Literatur
2.
Zurück zum Zitat Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration: principles and methods. Lyon: IARC Sci Publ No. 95; 1991. Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration: principles and methods. Lyon: IARC Sci Publ No. 95; 1991.
3.
Zurück zum Zitat Moreno V, González JR, Soler M, Bosch FX, Kogevinas M, Borràs JM. Estimación de la incidencia de cáncer en España: período 1993–1996. Gac Sanit. 2001;15(5):380–8.CrossRefPubMed Moreno V, González JR, Soler M, Bosch FX, Kogevinas M, Borràs JM. Estimación de la incidencia de cáncer en España: período 1993–1996. Gac Sanit. 2001;15(5):380–8.CrossRefPubMed
4.
Zurück zum Zitat López-Abente G, Pollán M, Aragonés N, Pérez B, Gómez B, Hernández Barrera V, et al. Situación del cáncer en España: Incidencia. An Sist Sanit Navar. 2004;27(2):165–73.CrossRefPubMed López-Abente G, Pollán M, Aragonés N, Pérez B, Gómez B, Hernández Barrera V, et al. Situación del cáncer en España: Incidencia. An Sist Sanit Navar. 2004;27(2):165–73.CrossRefPubMed
5.
Zurück zum Zitat Sanchez MJ, Payer T, de Angelis R, Larrañaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;21(Suppl 3):iii30–6.PubMed Sanchez MJ, Payer T, de Angelis R, Larrañaga N, Capocaccia R, Martinez C. Cancer incidence and mortality in Spain: estimates and projections for the period 1981–2012. Ann Oncol. 2010;21(Suppl 3):iii30–6.PubMed
7.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr.
8.
Zurück zum Zitat Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, Peris-Bonet R, et al. Population-based cancer registries in Spain and their role in cancer control. Ann Oncol. 2010;21(Suppl 3):iii3–13.PubMed Navarro C, Martos C, Ardanaz E, Galceran J, Izarzugaza I, Peris-Bonet R, et al. Population-based cancer registries in Spain and their role in cancer control. Ann Oncol. 2010;21(Suppl 3):iii3–13.PubMed
9.
Zurück zum Zitat World Health Organization. International Statistical classification of diseases and related health problems. 10th revision. Geneva: WHO; 1992. World Health Organization. International Statistical classification of diseases and related health problems. 10th revision. Geneva: WHO; 1992.
10.
Zurück zum Zitat Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38(1):99–166.CrossRefPubMed Bray F, Sankila R, Ferlay J, Parkin DM. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer. 2002;38(1):99–166.CrossRefPubMed
11.
Zurück zum Zitat Møller B, Fekjær H, Hakulinen T, Sigvaldason H, Storm HH, Talbäck M, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22:2751–66.CrossRefPubMed Møller B, Fekjær H, Hakulinen T, Sigvaldason H, Storm HH, Talbäck M, et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. Stat Med. 2003;22:2751–66.CrossRefPubMed
13.
Zurück zum Zitat Rapiti E, Guarnori S, Pastoors B, Miralbell R, Usel M. Planning for the future: cancer incidence projections in Switzerland up to 2019. BMC Public Health. 2014;14:102.CrossRefPubMedPubMedCentral Rapiti E, Guarnori S, Pastoors B, Miralbell R, Usel M. Planning for the future: cancer incidence projections in Switzerland up to 2019. BMC Public Health. 2014;14:102.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Rébillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A, et al. Incidence and mortality of urological cancers in 2012 in France. Prog Urol. 2013;23(Suppl 2):S57–65.CrossRefPubMed Rébillard X, Grosclaude P, Leone N, Velten M, Coureau G, Villers A, et al. Incidence and mortality of urological cancers in 2012 in France. Prog Urol. 2013;23(Suppl 2):S57–65.CrossRefPubMed
15.
Zurück zum Zitat Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M. Cancer screening in Spain. Ann Oncol. 2010;21(Suppl 3):iii43–51.PubMed Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M. Cancer screening in Spain. Ann Oncol. 2010;21(Suppl 3):iii43–51.PubMed
18.
Zurück zum Zitat Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al., editors. Cancer incidence in five continents, vol. X (electronic version) Lyon: IARC; (2013) http://ci5.iarc.fr. Accessed 6 June 2016 (printed version: IARC Scientific Publication No. 164, 2014). Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, et al., editors. Cancer incidence in five continents, vol. X (electronic version) Lyon: IARC; (2013) http://​ci5.​iarc.​fr. Accessed 6 June 2016 (printed version: IARC Scientific Publication No. 164, 2014).
19.
Zurück zum Zitat Bashir S, Estève J. Analysing the difference due to risk and demographic factors for incidence or mortality. Int J Epidemiol. 2000;29(5):878–84.CrossRefPubMed Bashir S, Estève J. Analysing the difference due to risk and demographic factors for incidence or mortality. Int J Epidemiol. 2000;29(5):878–84.CrossRefPubMed
20.
Zurück zum Zitat Peris R, Felipe S, Valero S, Pardo E. Cáncer infantil en España. Estadísticas 1980–2014. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2015. http://www.uv.es/rnti/informes.html (Edición Preliminar, CD-Rom). Peris R, Felipe S, Valero S, Pardo E. Cáncer infantil en España. Estadísticas 1980–2014. Registro Español de Tumores Infantiles (RETI-SEHOP). Valencia: Universitat de València; 2015. http://​www.​uv.​es/​rnti/​informes.​html (Edición Preliminar, CD-Rom).
21.
Zurück zum Zitat Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999–2007: results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217–30.CrossRef Marcos-Gragera R, Mallone S, Kiemeney LA, Vilardell L, Malats N, Allory Y, et al. Urinary tract cancer survival in Europe 1999–2007: results of the population-based study EUROCARE-5. Eur J Cancer. 2015;51:2217–30.CrossRef
22.
Zurück zum Zitat Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRefPubMed
23.
Zurück zum Zitat International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Tobacco Smoke and Involuntary Smoking, vol. 83. Lyon: IARC; 2004. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Tobacco Smoke and Involuntary Smoking, vol. 83. Lyon: IARC; 2004.
24.
Zurück zum Zitat International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Ionizing radiation, part 1: X- and gamma-radiation, and neutrons, vol. 75. Lyon: IARC; 2000. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Ionizing radiation, part 1: X- and gamma-radiation, and neutrons, vol. 75. Lyon: IARC; 2000.
25.
Zurück zum Zitat Büchner FL, Bueno-de-Mesquita HB, Ros MM, Overvad K, Dahm CC, Hansen L, et al. Variety in fruit and vegetable consumption and the risk of lung cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev. 2010;19(9):2278–86.CrossRef Büchner FL, Bueno-de-Mesquita HB, Ros MM, Overvad K, Dahm CC, Hansen L, et al. Variety in fruit and vegetable consumption and the risk of lung cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomark Prev. 2010;19(9):2278–86.CrossRef
26.
Zurück zum Zitat Instituto Nacional de Estadística (INE). Encuesta Nacional de Salud de España. Estudios nacionales de consumo de tabaco 1978–1982. (1978). Instituto Nacional de Estadística (INE). Encuesta Nacional de Salud de España. Estudios nacionales de consumo de tabaco 1978–1982. (1978).
28.
Zurück zum Zitat Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomark Prev. 2009;18(2):541–50.CrossRef Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomark Prev. 2009;18(2):541–50.CrossRef
30.
Zurück zum Zitat Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155–64.CrossRefPubMed Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. Int J Cancer. 2008;122(1):155–64.CrossRefPubMed
31.
32.
Zurück zum Zitat Bosetti C, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005. Ann Oncol. 2007;18:431–46.CrossRefPubMed Bosetti C, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005. Ann Oncol. 2007;18:431–46.CrossRefPubMed
33.
Zurück zum Zitat Mannetje A, Kogevinas M, Chang-Claude J, Cordier S, Gonzalez CA, Hours M, et al. Occupation and bladder cancer in European women. Cancer Causes Control. 1999;10:209–17.CrossRefPubMed Mannetje A, Kogevinas M, Chang-Claude J, Cordier S, Gonzalez CA, Hours M, et al. Occupation and bladder cancer in European women. Cancer Causes Control. 1999;10:209–17.CrossRefPubMed
35.
Zurück zum Zitat Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health. 2001;25(4):263–70.PubMed Bagnardi V, Blangiardo M, La Vecchia C, Corrao G. Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health. 2001;25(4):263–70.PubMed
37.
38.
Zurück zum Zitat Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.CrossRefPubMed Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–83.CrossRefPubMed
39.
Zurück zum Zitat Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114(6):1169–79.CrossRefPubMed Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114(6):1169–79.CrossRefPubMed
40.
Zurück zum Zitat Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—part C: metals, arsenic, dusts, and fibres. Lancet Oncol. 2009;10(5):453–4.CrossRefPubMed Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—part C: metals, arsenic, dusts, and fibres. Lancet Oncol. 2009;10(5):453–4.CrossRefPubMed
41.
42.
Zurück zum Zitat López-Abente G, Ardanaz E, Torrella-Ramos A, Mateos A, Delgado-Sanz D, Chirlaque MD, For the Colorectal Cancer Working Group. Changes in colorectal cancer incidence and mortality trends in Spain. Ann Oncol. 2010;21(Suppl 3):iii76–82.PubMed López-Abente G, Ardanaz E, Torrella-Ramos A, Mateos A, Delgado-Sanz D, Chirlaque MD, For the Colorectal Cancer Working Group. Changes in colorectal cancer incidence and mortality trends in Spain. Ann Oncol. 2010;21(Suppl 3):iii76–82.PubMed
43.
45.
Zurück zum Zitat Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11(7):579–88.CrossRefPubMed Platz EA, Willett WC, Colditz GA, Rimm EB, Spiegelman D, Giovannucci E. Proportion of colon cancer risk that might be preventable in a cohort of middle-aged US men. Cancer Causes Control. 2000;11(7):579–88.CrossRefPubMed
46.
Zurück zum Zitat Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958–72.CrossRefPubMed Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol. 2011;22(9):1958–72.CrossRefPubMed
47.
Zurück zum Zitat Hooker CM, Gallicchio L, Genkinger JM, Comstock GW, Alberg AJ. A prospective cohort study of rectal cancer risk in relation to active cigarette smoking and passive smoke exposure. Ann Epidemiol. 2008;18:28–35.CrossRefPubMed Hooker CM, Gallicchio L, Genkinger JM, Comstock GW, Alberg AJ. A prospective cohort study of rectal cancer risk in relation to active cigarette smoking and passive smoke exposure. Ann Epidemiol. 2008;18:28–35.CrossRefPubMed
48.
Zurück zum Zitat Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13.CrossRefPubMed Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603–13.CrossRefPubMed
49.
Zurück zum Zitat García A, Marzo M, Mascort J, Quintero E, García-Alfonso P, López-Ibor C, et al. Prevención del cáncer colorectal. Aten Primaria. 2009;41(3):127–8.CrossRef García A, Marzo M, Mascort J, Quintero E, García-Alfonso P, López-Ibor C, et al. Prevención del cáncer colorectal. Aten Primaria. 2009;41(3):127–8.CrossRef
52.
Zurück zum Zitat Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51(6):849–52.CrossRefPubMedPubMedCentral Malka D, Hammel P, Maire F, Rufat P, Madeira I, Pessione F, et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut. 2002;51(6):849–52.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Tascilar M, van Rees BP, Sturm PD, Tytgat GN, Hruban RH, Goodman SN, et al. Pancreatic cancer after remote peptic ulcer surgery. J Clin Pathol. 2002;55(5):340–5.CrossRefPubMedPubMedCentral Tascilar M, van Rees BP, Sturm PD, Tytgat GN, Hruban RH, Goodman SN, et al. Pancreatic cancer after remote peptic ulcer surgery. J Clin Pathol. 2002;55(5):340–5.CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.CrossRefPubMed Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103–23.CrossRefPubMed
55.
Zurück zum Zitat Cabanes A, Pérez-Gómez B, Aragonés N, Pollán M, López-Abente G. La situación del cáncer en España, 1975–2006. Madrid: Instituto de Salud Carlos III; 2009. Cabanes A, Pérez-Gómez B, Aragonés N, Pollán M, López-Abente G. La situación del cáncer en España, 1975–2006. Madrid: Instituto de Salud Carlos III; 2009.
56.
Zurück zum Zitat Reeves GK, Pirie K, Green J, Bull D. Beral V; Million Women Study Collaborators. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer. 2009;100(3):538–44.CrossRefPubMedPubMedCentral Reeves GK, Pirie K, Green J, Bull D. Beral V; Million Women Study Collaborators. Reproductive factors and specific histological types of breast cancer: prospective study and meta-analysis. Br J Cancer. 2009;100(3):538–44.CrossRefPubMedPubMedCentral
57.
Zurück zum Zitat Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006. Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. 3rd ed. New York: Oxford University Press; 2006.
58.
Zurück zum Zitat Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res. 2008;14(9):2861–9.CrossRefPubMed Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, et al. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res. 2008;14(9):2861–9.CrossRefPubMed
59.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996;54(3 Suppl):1S–106S. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996;54(3 Suppl):1S–106S.
60.
Zurück zum Zitat Benet Rodríguez M, Carvajal García-Pando A, García del Pozo J, Alvarez Requejo A, Vega Alonso T. Hormonal replacement therapy in Spain. Med Clin (Barc). 2002;119(1):4–8.CrossRef Benet Rodríguez M, Carvajal García-Pando A, García del Pozo J, Alvarez Requejo A, Vega Alonso T. Hormonal replacement therapy in Spain. Med Clin (Barc). 2002;119(1):4–8.CrossRef
63.
Zurück zum Zitat Pollán M, Michelena MJ, Ardanaz E, Izquierdo A, Sánchez-Pérez MJ, Torrella A. Breast Cancer Working Group. Breast cancer incidence in Spain before, during and after the implementation of screening programmes. Ann Oncol. 2010;21(Suppl 3):iii97–102.PubMed Pollán M, Michelena MJ, Ardanaz E, Izquierdo A, Sánchez-Pérez MJ, Torrella A. Breast Cancer Working Group. Breast cancer incidence in Spain before, during and after the implementation of screening programmes. Ann Oncol. 2010;21(Suppl 3):iii97–102.PubMed
64.
Zurück zum Zitat Puig-Vives M, Pollan M, Rue M, Osca-Gelis G, Saez M, Izquierdo A, et al. Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983–2007. Breast. 2012;21(5):646–51.CrossRefPubMed Puig-Vives M, Pollan M, Rue M, Osca-Gelis G, Saez M, Izquierdo A, et al. Rapid increase in incidence of breast ductal carcinoma in situ in Girona, Spain 1983–2007. Breast. 2012;21(5):646–51.CrossRefPubMed
65.
Zurück zum Zitat International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–91.CrossRef International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–91.CrossRef
66.
Zurück zum Zitat International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part A: pharmaceuticals, vol. 100A. Lyon: IARC; 2012. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. A review of human carcinogens. Part A: pharmaceuticals, vol. 100A. Lyon: IARC; 2012.
68.
Zurück zum Zitat Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–14.CrossRef Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303–14.CrossRef
70.
Zurück zum Zitat Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103(3):1122–9.CrossRefPubMed Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecol Oncol. 2006;103(3):1122–9.CrossRefPubMed
71.
Zurück zum Zitat Larrañaga N, Galceran J, Ardanaz E, Franch P, Navarro C, Sánchez MJ, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol. 2010;21(Suppl 3):iii83–9.PubMed Larrañaga N, Galceran J, Ardanaz E, Franch P, Navarro C, Sánchez MJ, et al. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol. 2010;21(Suppl 3):iii83–9.PubMed
72.
73.
Zurück zum Zitat Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risc factor for prostate cancer. A meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100:693–701.CrossRefPubMedPubMedCentral Huncharek M, Haddock KS, Reid R, Kupelnick B. Smoking as a risc factor for prostate cancer. A meta-analysis of 24 prospective cohort studies. Am J Public Health. 2010;100:693–701.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014;202:27–37.CrossRefPubMed Discacciati A, Wolk A. Lifestyle and dietary factors in prostate cancer prevention. Recent Results Cancer Res. 2014;202:27–37.CrossRefPubMed
75.
Zurück zum Zitat Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52.CrossRefPubMed Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273(7):548–52.CrossRefPubMed
76.
Zurück zum Zitat Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas—an update. J Intern Med. 2008;264(6):514–27.CrossRefPubMed Smedby KE, Askling J, Mariette X, Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas—an update. J Intern Med. 2008;264(6):514–27.CrossRefPubMed
78.
Zurück zum Zitat Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sánchez MJ, Garau I, For the Non-Hodgkin’s Lymphoma Working Group. Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3):iii90–6.PubMed Marcos-Gragera R, Pollán M, Chirlaque MD, Gumà J, Sánchez MJ, Garau I, For the Non-Hodgkin’s Lymphoma Working Group. Attenuation of the epidemic increase in non-Hodgkin’s lymphomas in Spain. Ann Oncol. 2010;21(Suppl 3):iii90–6.PubMed
79.
Zurück zum Zitat Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822–6.CrossRefPubMed Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822–6.CrossRefPubMed
80.
Zurück zum Zitat Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355(9199):165–9.CrossRefPubMed Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355(9199):165–9.CrossRefPubMed
82.
Zurück zum Zitat Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.CrossRefPubMed Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(Suppl 61):1–6.CrossRefPubMed
83.
Zurück zum Zitat Clark LN, Shin DB, Troxel AB, Khan S, Sober AJ, Ming ME. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol. 2007;56(5):768–73.CrossRefPubMed Clark LN, Shin DB, Troxel AB, Khan S, Sober AJ, Ming ME. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol. 2007;56(5):768–73.CrossRefPubMed
84.
Zurück zum Zitat Ocaña-Riola R, Martínez-García C, Serrano S, Buendia-Eisman A, Ruiz-Baena C, Canela-Soler J. Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985–1992. Eur J Epidemiol. 2001;17(2):169–74.CrossRefPubMed Ocaña-Riola R, Martínez-García C, Serrano S, Buendia-Eisman A, Ruiz-Baena C, Canela-Soler J. Population-based study of cutaneous malignant melanoma in the Granada province (Spain), 1985–1992. Eur J Epidemiol. 2001;17(2):169–74.CrossRefPubMed
85.
Zurück zum Zitat Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control. 2001;12(1):69–82.CrossRefPubMed Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control. 2001;12(1):69–82.CrossRefPubMed
86.
Zurück zum Zitat Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.PubMed Marcos-Gragera R, Vilar-Coromina N, Galceran J, Borras J, Cleries R, Ribes J, et al. Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? J Eur Acad Dermatol Venereol. 2010;24(9):1083–8.PubMed
Metadaten
Titel
Cancer incidence in Spain, 2015
verfasst von
J. Galceran
A. Ameijide
M. Carulla
A. Mateos
J. R. Quirós
D. Rojas
A. Alemán
A. Torrella
M. Chico
M. Vicente
J. M. Díaz
N. Larrañaga
R. Marcos-Gragera
M. J. Sánchez
J. Perucha
P. Franch
C. Navarro
E. Ardanaz
J. Bigorra
P. Rodrigo
R. Peris Bonet
REDECAN Working Group
Publikationsdatum
16.01.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 7/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1607-9

Weitere Artikel der Ausgabe 7/2017

Clinical and Translational Oncology 7/2017 Zur Ausgabe

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.